Floatz logo

Irinotecan

Myeloproliferative Disorder

OHSU Knight Cancer InstituteSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Myeloproliferative Disorder cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
The First Affiliated Hospital of Soochow University
Phase 2B
Campath
University of Chicago
Phase 2B
Tocilizumab
Memorial Sloan Kettering Cancer Center
Phase 2B
Equine Atg
Masonic Cancer Center, University of Minnesota
Phase 2B
Gm-Csf
Beth Israel Deaconess Medical Center
Phase 2B

View all 9 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →